| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 6.48▼ | 6.48▲ | 6.48▼ | 5.83▲ | 5.31▲ |
| MA10 | 6.49▼ | 6.47▲ | 6.32▲ | 5.37▲ | 4.98▲ |
| MA20 | 6.48▼ | 6.30▲ | 6.10▲ | 5.11▲ | 4.92▲ |
| MA50 | 6.48▲ | 5.93▲ | 5.57▲ | 4.88▲ | 5.00▲ |
| MA100 | 6.35▲ | 5.52▲ | 5.22▲ | 4.92▲ | 3.71▲ |
| MA200 | 6.13▲ | 5.18▲ | 4.93▲ | 5.36▲ | 2.87▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.001▼ | -0.007▼ | 0.024▲ | 0.154▲ | 0.127▲ |
| RSI | 50.091▲ | 68.608▲ | 78.481▲ | 76.354▲ | 62.497▲ |
| STOCH | 52.334 | 61.077 | 83.284▲ | 84.318▲ | 68.754 |
| WILL %R | -56.522 | -18.321▲ | -13.333▲ | -6.512▲ | -5.479▲ |
| CCI | 62.150 | 55.348 | 77.312 | 202.143▲ | 277.881▲ |
|
Monday, June 22, 2026 02:05 PM
Explore how oncology data season is drawing attention to Nuvation Bio, Arcus Biosciences, and smaller cancer-focused biotech developers.
|
|
Friday, June 19, 2026 12:09 PM
Biotech penny stocks including Nuvation Bio and Anixa Biosciences draw focus as clinical milestones and regulatory steps shape sentiment.
|
|
Tuesday, June 16, 2026 12:29 PM
Nuvation Bio Inc. (NYSE:NUVB) is one of the Best Penny Stocks That Could Skyrocket in 2026. On June 9, Reuters reported that GSK agreed to acquire cancer drug developer Nuvalent for a deal worth $10.6 ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 24/06/26 | 6.08 | 6.60 | 6.08 | 6.46 | 9,429,033 |
| 23/06/26 | 5.71 | 6.0898 | 5.66 | 6.04 | 4,195,169 |
| 22/06/26 | 5.64 | 5.875 | 5.61 | 5.76 | 4,154,965 |
| 18/06/26 | 5.44 | 5.575 | 5.33 | 5.56 | 3,705,571 |
| 17/06/26 | 5.16 | 5.355 | 5.105 | 5.33 | 5,412,428 |
| 16/06/26 | 5.15 | 5.259 | 5.035 | 5.12 | 3,623,240 |
| 15/06/26 | 5.04 | 5.165 | 4.87 | 5.14 | 4,181,678 |
| 12/06/26 | 4.86 | 5.21 | 4.86 | 4.92 | 5,245,502 |
| 11/06/26 | 4.55 | 4.805 | 4.45 | 4.76 | 3,195,701 |
| 10/06/26 | 4.84 | 4.96 | 4.52 | 4.58 | 6,594,976 |
|
|
||||
|
|
||||
|
|